The National Medical Insurance Bureau's special campaign continues to crack down on illegal chains involved in "reflow drugs."

Xinhua News Agency, Beijing, April 2 (Reporter Xu Penghang, Peng Yunjia) The reporter learned on April 2 from the National Healthcare Security Administration that the Office of the National Healthcare Security Administration recently issued a notice titled “Notice on Deepening the Special Campaign to Crack Down on Illegal and Irregular Issues in the Healthcare Security Drug Sector,” clarifying that starting in April 2026, the special campaign to further crack down on illegal and irregular issues in the healthcare security drug sector will continue to be carried out nationwide, using the verification of suspicious leads related to drug traceability codes as a handle.

It is reported that the special campaign is divided into two phases: the first phase is from April to July 2026, and the second phase is from September to November 2026. The National Healthcare Security Administration will issue batches of suspicious leads regarding duplicate settlements involving drug traceability codes at the beginning of April 2026 and at the beginning of September 2026, respectively.

Local healthcare security departments, together with relevant departments, will coordinate with nationwide leads issued by the state, leads on prescribing excessive quantities of drugs locally, and leads from public reports and complaints, among others, and will conduct in-depth verification and remediation to precisely crack down on illegal and irregular issues such as the sale and resale of healthcare security “returned drugs” (returned drugs) through channels, swapping healthcare security drugs, “washing” or “faking” medical insurance credentials (faking medical insurance credentials), forging prescriptions, hoarding cards for purchase (hoarding cards for purchase), and topping off consumption at year-end (topping off consumption at year-end), and will promptly recover losses to healthcare security funds.

In addition, depending on the severity of the circumstances, corresponding measures will be taken, including conducting interviews and reminders, requiring rectification within a time limit, suspending healthcare security settlement, terminating service agreements, administering point deductions for healthcare insurance payment eligibility, and transferring cases to the competent industry authorities, judicial organs, and discipline inspection and supervision authorities, among others.

The notice emphasizes that it will focus on all links and the entire process of the resale of “returned drugs” and will continuously strengthen a “through” approach crackdown on all categories of persons involved in the case, including professional prescribers (prescribers), drug peddlers, and illegal and irregular wholesale drug enterprises and pharmaceutical institutions, and will completely sever the illegal chain of “prescribing—reselling—returning—selling.”

Healthcare security departments will work with relevant departments to carry out joint inspections and joint punishments, and will strictly prevent “returned drugs” from flowing to non-healthcare-security-designated medical and pharmaceutical institutions, online drug-selling platforms, or from being resold again in the form of self-payment.

(Editor: Wen Jing)

Keywords:

                                                            National Healthcare Security Administration
                                                            Drugs